Literature DB >> 2965164

Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.

J D Gray1, D A Horwitz.   

Abstract

In the absence of antigenic or mitogenic stimulation, certain peripheral blood lymphocytes exhibit proliferative and lymphokine-activated killer (LAK) cell activities when cultured with recombinant IL-2. Both activities were found to be an exclusive property of lymphocytes expressing type 3 complement receptors (CR3) identified by anti-CD11 monoclonal antibodies. CD11+ lymphocytes were then fractionated into three subsets by two-color flow cytometry. These included CD16+ cells, which display distinctive Fc receptors for IgG (CD16). Using anti-CD5, the CD11+ CD16- lymphocytes were separated into non-T cell and T cell subsets. The two non-T cell subsets (CD11+ CD16+ and CD11+ CD16- CD5-), but not the T cell subset (CD11+ CD16- CD5+), could proliferate in response to IL-2. Both CD11+ non-T cell subsets, but not the CD11+ T cell subset, had the capacity to mediate natural killer cell activity. However, all three CD11+ lymphocyte subsets were capable of generating LAK activity. These findings are consistent with the concept that two signals are required to stimulate T cells to proliferate. However, at least a small subset of blood T cells can be activated by IL-2 to become LAK cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965164      PMCID: PMC329656          DOI: 10.1172/JCI113442

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Authors:  M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions.

Authors:  M Sharon; R D Klausner; B R Cullen; R Chizzonite; W J Leonard
Journal:  Science       Date:  1986-11-14       Impact factor: 47.728

3.  Evidence by reactivity with hybridoma antibodies for a probable myeloid origin of peripheral blood cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Authors:  H D Kay; D A Horwitz
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

4.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes.

Authors:  L T Bich-Thuy; H C Lane; A S Fauci
Journal:  Cell Immunol       Date:  1986-04-01       Impact factor: 4.868

6.  A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors.

Authors:  M Dukovich; Y Wano; P Katz; B R Cullen; J H Kehrl; W C Greene
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

7.  Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.

Authors:  J E Talmadge; R H Wiltrout; D F Counts; R B Herberman; T McDonald; J R Ortaldo
Journal:  Cell Immunol       Date:  1986-10-15       Impact factor: 4.868

8.  Studies on human blood lymphocytes with iC3b (type 3) complement receptors. II. Characterization of subsets which regulate pokeweed mitogen-induced lymphocyte proliferation and immunoglobulin synthesis.

Authors:  W Abo; J D Gray; A C Bakke; D A Horwitz
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

9.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

10.  Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.

Authors:  K Teshigawara; H M Wang; K Kato; K A Smith
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

View more
  7 in total

1.  To be or not to be B7.

Authors:  Xingxing Zang; James P Allison
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

2.  CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents.

Authors:  S Muto; V Vĕtvicka; G D Ross
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

3.  Herpes simplex virus-infected cells disarm killer lymphocytes.

Authors:  D L Confer; G M Vercellotti; D Kotasek; J L Goodman; A Ochoa; H S Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

4.  Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Ti gamma/delta or TNK phenotype.

Authors:  U Testa; A Care; E Montesoro; C Fossati; G Giannella; R Masciulli; M Fagioli; D Bulgarini; D Habetswallner; G Isacchi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.

Authors:  H Shau; J D Gray; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.

Authors:  D G Morris; H F Pross
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

7.  Purification and characterization of a human membrane protein that activates the alternative complement pathway and allows the deposition of homologous complement C3.

Authors:  M Matsumoto; F Yamashita; K Iida; M Tomita; T Seya
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.